Universidade Federal de São Paulo, São Paulo, BrazilAstraZeneca, Macclesfield, Cheshire, EnglandUniversidade Federal de São Paulo, São Paulo, BrazilWeb of Scienc
AIM: The metabolic syndrome (MS) increases the risk of coronary heart disease, yet few data are ava...
Aims The efficacy and safety of rosuvastatin, atorvastatin, and placebo were compared in patients wi...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Background. International guidelines emphasize the need to achieve recommended low-density lipoprote...
Background: International guidelines emphasize the need to achieve recommended low-density lipoprote...
Item does not contain fulltextAIMS: The efficacy and safety of rosuvastatin, atorvastatin, and place...
Background: To compare the drugs: Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslip...
AbstractBackground:The majority of clinical trials investigating the clinical benefits of lipid-lowe...
Background: Statins are recognized to be the first line of therapy for lowering cholesterol and have...
Background: Patients at high risk of cardiovascular disease frequently fail to reach recommended low...
Furio Colivicchi,1 Catarina Sternhufvud,2 Sanjay K Gandhi3 1Cardiology Division, Emergency Departmen...
Background: Hypercholesterolemia patients are at high risk of coronary heart disease. National chole...
Pharmacotherapy is one of the most important measures for improving the health status of patients, w...
The objectives of this study were to compare the effectiveness of atorvastatin, rosuvastatin, and si...
Toivo Laks1, Ester Keba2, Mariann Leiner3, Eero Merilind4, Mall Petersen5, Sirje Reinmets6, Sille V&...
AIM: The metabolic syndrome (MS) increases the risk of coronary heart disease, yet few data are ava...
Aims The efficacy and safety of rosuvastatin, atorvastatin, and placebo were compared in patients wi...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Background. International guidelines emphasize the need to achieve recommended low-density lipoprote...
Background: International guidelines emphasize the need to achieve recommended low-density lipoprote...
Item does not contain fulltextAIMS: The efficacy and safety of rosuvastatin, atorvastatin, and place...
Background: To compare the drugs: Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslip...
AbstractBackground:The majority of clinical trials investigating the clinical benefits of lipid-lowe...
Background: Statins are recognized to be the first line of therapy for lowering cholesterol and have...
Background: Patients at high risk of cardiovascular disease frequently fail to reach recommended low...
Furio Colivicchi,1 Catarina Sternhufvud,2 Sanjay K Gandhi3 1Cardiology Division, Emergency Departmen...
Background: Hypercholesterolemia patients are at high risk of coronary heart disease. National chole...
Pharmacotherapy is one of the most important measures for improving the health status of patients, w...
The objectives of this study were to compare the effectiveness of atorvastatin, rosuvastatin, and si...
Toivo Laks1, Ester Keba2, Mariann Leiner3, Eero Merilind4, Mall Petersen5, Sirje Reinmets6, Sille V&...
AIM: The metabolic syndrome (MS) increases the risk of coronary heart disease, yet few data are ava...
Aims The efficacy and safety of rosuvastatin, atorvastatin, and placebo were compared in patients wi...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
DOI
Add to ORKG